Companies · Biotechnology

AOA DX Inc.Summer 2021Active

Denver · CO, USA; Cambridge, MA, USA · Biotechnology · founded 2021 · https://www.aoadx.com/

Diligence memoA one-page analyst read on AOA DX Inc. — recommendation, valuation, rhythm, risks.
$38.7M
Total raised · real
5
Rounds
4.4×
Latest step-up
Top 23%
Sector rank · raised
Series B
Latest stage · inferred · Wed Oct 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

AOA DX Inc. looks under-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.43× the median modeled value of Series B Biotechnology companies in 2025–2027 (94 peers) — value vs value, same stage and era.
Active
  • Last raise 9 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

AOA DX Inc. is one of 4293 Biotechnology companies tracked from Denver, CO, USA; Cambridge, MA, USA, on record since 2021. By capital raised it ranks in the upper tier (ahead of 78% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst

Blood Test for Early Detection of Ovarian Cancer

AOA Dx is developing the next frontier in early-stage cancer detection for women through our pioneering work in glycolipids and proprietary biomarker technology.

HealthcareDiagnosticsWomen's Health
Find AOA DX Inc. online

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
40
Investors (latest)
2025-10-01
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeed · 2021-02-26 Raised $2.5M (real) Modeled valuation $77M (est)$2.5M$77MSeed2021Seed · 2021-11-03 Raised $2.6M (real) Modeled valuation $56M (est)$2.6M$56MSeed2021Series B · 2023-07-11 Raised $24M (real) Modeled valuation $256M (est)$24M$256MSeries B2023Series B · 2024-12-05 Raised $1.8M (real) Modeled valuation $11M (est)$1.8M$11MSeries B2024Series B · 2025-10-01 Raised $8.1M (real) Modeled valuation $34M (est)$8.1M$34MSeries B2025+$2.6M+$24M+$1.8M+$8.1MCumulative $39M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.5M · 2021
Seed extension$2.6M · 2021
Series B$23.6M · 2023no Series A on file
Series B extension$1.8M · 2024
Series B extension$8.1M · 2025

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$33.7M
Base estimate est.
$16.2M
Conservative case
$47.5M
Upside case
$44.9M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $77.2M · 2021-02-262021Seed · modeled $55.8M · 2021-11-03Series B · modeled $256.0M · 2023-07-11Series B · modeled $10.9M · 2024-12-05Series B · modeled $33.7M · 2025-10-012025
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
0.8 yr
Elapsed time used
0.8 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
14 mo
Avg between rounds
$8.4M/yr
Capital velocity
5.3 yr
On record since
2021
First round
5
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 5.4× above median
This company$38.7M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.5× of median
This company$8.1M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 0.5× of median
This company$33.7M
Sector median$64.2M

Raised more than 78% of sector peers (real $). Modeled value above 37% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #70 of 94.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)MarvelBiome, Inc. · Series B Raised $54.9M · modeled $163.2M (est)Iantrek, Inc. · Series B Raised $58.2M · modeled $152.4M (est)Dualitas Therapeutics, Inc. · Series B Raised $32.6M · modeled $150.4M (est)Antares Therapeutics, Inc. · Series B Raised $70.0M · modeled $149.7M (est)OrthoBio Therapeutics, Inc. · Series B Raised $31.4M · modeled $147.5M (est)Medcura, Inc. · Series B Raised $40.9M · modeled $145.0M (est)Neurolutions Inc · Series B Raised $26.5M · modeled $144.9M (est)Renasant Bio, Inc. · Series B Raised $55.5M · modeled $144.0M (est)Caldera Therapeutics, Inc. · Series B Raised $37.5M · modeled $139.2M (est)VitriVax, Inc. · Series B Raised $29.4M · modeled $136.9M (est)DiaMedica Therapeutics Inc. · Series B Raised $110.4M · modeled $136.3M (est)OmniAb, Inc. · Series B Raised $30.0M · modeled $130.5M (est)AOA DX Inc. (this company) Raised $38.7M · modeled $33.7M (est)AOA DX Inc.
CompanyStageRaised · realValue · estvs peer med.
MarvelBiome, Inc.Series B$54.9M$163.2M2.11×
Iantrek, Inc.Series B$58.2M$152.4M1.97×
Dualitas Therapeutics, Inc.Series B$32.6M$150.4M1.94×
Antares Therapeutics, Inc.Series B$70.0M$149.7M1.93×
OrthoBio Therapeutics, Inc.Series B$31.4M$147.5M1.90×
Medcura, Inc.Series B$40.9M$145.0M1.87×
Neurolutions IncSeries B$26.5M$144.9M1.87×
Renasant Bio, Inc.Series B$55.5M$144.0M1.86×
Caldera Therapeutics, Inc.Series B$37.5M$139.2M1.80×
VitriVax, Inc.Series B$29.4M$136.9M1.77×
DiaMedica Therapeutics Inc.Series B$110.4M$136.3M1.76×
OmniAb, Inc.Series B$30.0M$130.5M1.68×
AOA DX Inc. this companySeries B$38.7M$33.7M0.43×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.5M2021-02-26$12.5M$77.2M90%
Seed$2.6M2021-11-03$13.2M$55.8M90%
Series B$23.6M2023-07-11$131.2M$256.0M90%
Series B$1.8M2024-12-05$10.3M$10.9M90%
Series B$8.1M2025-10-01$44.9M$33.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.5M2021-02-26
    • First recorded raise — entered as Seed.
    • 38 investors on this round.
  2. Seed$2.6M2021-11-03
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 33 investors on this round.
  3. Series B$23.6M2023-07-11
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round 8.9× larger than the prior — scaling up.
    • 119 investors on this round.
  4. Series B$1.8M2024-12-05
    • Raised 17 mo later, in step with the ~14 mo sector norm.
    • Round 12.8× smaller than the prior — bridge or down round.
    • 15 investors on this round.
  5. Series B$8.1M2025-10-01
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round 4.4× larger than the prior — scaling up.
    • 40 investors on this round.
Intelligence
2026 ~Q4
Modeled next raise · ~14mo cadence
$24.3M
Modeled next size est.range $15.8M$38.8M
4.4×
Last step-up
$8.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
John Friedman8 other2023-07
Surbhi Sarna1 other2021-11
Abigail James Mcelhinny2024-12
Alexander Fisher2021-11
Alexander James Fisher2021-02
Anna Milik Jeter2021-02
Oriana Papin-Zoghbi2023-07
Oriana Zoghbi-Harb2021-02
Registry & provenance

AOA DX Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1869920
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Nora Therapeutics, Inc.BiotechnologySeries B$38.3M$39.7Msame sector · same stage
Lysosomal Therapeutics, Inc.BiotechnologySeries B$38.0M$39.7Msame sector · same stage
Unigene Laboratories IncBiotechnologySeries B$37.8M$29.8Msame sector · same stage
Abpro CorpBiotechnologySeries B$42.4M$37.6Msame sector · same stage
Eleven Biotherapeutics, Inc.BiotechnologySeries B$43.3M$39.5Msame sector · same stage
i2O Therapeutics, Inc.BiotechnologySeries B$43.9M$35.0Msame sector · same stage
VIRxSYS CorpBiotechnologySeries B$44.6M$39.7Msame sector · same stage
SIRPant Immunotherapeutics, Inc.BiotechnologySeries B$32.4M$28.7Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Aortic Innovations LLCBiotechnologySeed$71.9M74%
Aortica CorpBiotechnologySeries A$37.1M74%
Early Stage Cancer Detection, Inc.BiotechnologyPre-Seed$7.4M73%
Delee Corp
Blood testing device for early diagnosis of cancer and treatment…
BiotechnologySeed$52.2M73%
A-Alpha Bio, Inc.Biotech / PharmaSeries B$465.2M72%
Hera Testing Laboratories, Inc.BiotechnologySeed$45.4M72%
Ora Biomedical, Inc.BiotechnologyPre-Seed$4.4M72%
Clear Gene
Our tests help eradicate cancer by telling doctors whether they got…
72%
Frequently asked
How much funding has AOA DX Inc. raised?
AOA DX Inc. has raised approximately $38.7M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is AOA DX Inc.'s estimated valuation?
Provath's modeled valuation for AOA DX Inc. is approximately $33.7M (modeled range $16.2M–$47.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is AOA DX Inc. at?
AOA DX Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Wed Oct 01.
What does AOA DX Inc. do and where is it based?
AOA DX Inc. operates in the Biotechnology sector, based in Denver, CO, USA; Cambridge, MA, USA. Blood Test for Early Detection of Ovarian Cancer
Explore related

See where AOA DX Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at AOA DX Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.